BDNF and Alzheimer disease: Considering the current results on cognitive decline with monoclonal anti-amyloid antibodies in patients with mild AD, we think it is of high relevance to summarize the recent literature on an additional mechanism for the treatment of AD, i.e., small-molecule positive allosteric modulators within the field of neurotrophins.